Stuttgart
03.03.25
08:25 Uhr
1,420 Euro
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.02. | Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report | 33 | GlobeNewswire (Europe) | Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of... ► Artikel lesen | |
| 10.01. | Orexo Announces Positive Data From Clinical Study Of OX640 Evaluating Allergic Reactions | 1 | RTTNews | ||
| 10.01. | Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis | 328 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical... ► Artikel lesen | |
| 18.12.24 | Abera and Orexo partner for vaccine powder formulations | 2 | Pharmaceutical Technology | ||
| 17.12.24 | Orexo, Abera to develop nasal powder vaccines based on AmorphOX technology | 2 | Seeking Alpha | ||
| 17.12.24 | Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology | 419 | PR Newswire | The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical... ► Artikel lesen | |
| OREXO Aktie jetzt für 0€ handeln | |||||
| 02.12.24 | Orexo exits depression DTx alliance with GAIA | 1 | pharmaphorum | ||
| 02.12.24 | Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis | 218 | GlobeNewswire (Europe) | Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for... ► Artikel lesen | |
| 25.10.24 | Orexo initiates new study of OX640 in participants with allergic rhinitis | 275 | PR Newswire | OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo's proprietary drug delivery... ► Artikel lesen | |
| 24.10.24 | Orexo AB reports Q3 results | 1 | Seeking Alpha | ||
| 24.10.24 | Orexo Interim Report Q3 2024 | 401 | PR Newswire | UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ --
Q3 2024 highlights
› Total net revenues of SEK 136.5 m (156.1)
› EBITDA of SEK -0.7 m (-9.5)
› Net earnings of SEK -41.9... ► Artikel lesen | |
| 04.10.24 | Orexo's Nomination Committee for the Annual General Meeting 2025 | 287 | PR Newswire | UPPSALA, Sweden, Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises... ► Artikel lesen | |
| 03.09.24 | Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024 | 291 | PR Newswire | UPPSALA, Sweden, Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY), today announces the company will participate in Pareto Securities' 15th Annual Healthcare Conference... ► Artikel lesen | |
| 17.07.24 | Orexo Q2 2024 Interim Report | 380 | PR Newswire | UPPSALA, Sweden, July 17, 2024 /PRNewswire/ --
Making progress, while the OX124 review time extended
Q2 2024 highlights
Total net revenues of SEK 154.0 m (157.7)EBITDA of SEK... ► Artikel lesen | |
| 16.07.24 | Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose | 377 | PR Newswire | UPPSALA, Sweden, July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food... ► Artikel lesen | |
| 10.07.24 | Orexo AB's sustainability work ranked among top 5% by EcoVadis | 430 | PR Newswire | UPPSALA, Sweden, July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world's most trusted... ► Artikel lesen | |
| 08.07.24 | Orexo: invitation to presentation of the Q2 2024 Interim Report | 386 | PR Newswire | UPPSALA, Sweden, July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET. The same day at 2 pm... ► Artikel lesen | |
| 10.05.24 | Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm | 901 | PR Newswire | UPPSALA, Sweden, May 10, 2024 /PRNewswire/ -- On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) successfully issued senior secured callable floating... ► Artikel lesen | |
| 08.05.24 | Orexo Q1 2024 Interim Report | 424 | PR Newswire | UPPSALA, Sweden, May 8, 2024 /PRNewswire/ --
Starting 2024 with a positive EBITDA
Q1 2024 highlights
Total net revenues of SEK 139.3 m (158.8)EBITDA of SEK 15.9 m (-41.1)Net... ► Artikel lesen | |
| 26.04.24 | Report from Orexo AB's annual general meeting, 26 April 2024 | 321 | PR Newswire | UPPSALA, Sweden, April 26, 2024 /PRNewswire/ --
Election of the board of directors and auditor
The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance... ► Artikel lesen |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 4,560 | -0,96 % | UNGLAUBLICHE Sondermeldung bei Aurora Cannabis Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| ABBVIE | 201,70 | -0,05 % | AKTIONÄR-Depotwert Gubra: Hammer-Deal mit AbbVie - die Details! | Paukenschlag zum Wochenstart: AKTIONÄR-Depotwert Gubra hat eine Lizenzvereinbarung mit dem Pharma-Riesen AbbVie unter Dach und Fach gebracht. Die Amerikaner sichern sich die Rechte an einem Amylin-Projekt... ► Artikel lesen | |
| TILRAY BRANDS | 0,650 | -0,46 % | UNGLAUBLICHE Sondermeldung bei Tilray Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| BRISTOL-MYERS SQUIBB | 57,02 | -0,19 % | Bristol Myers Squibb kündigt Dividenden für Stamm- und Vorzugsaktien an | ||
| TEVA | 15,300 | 0,00 % | Teva Pharmaceutical Industries Ltd: Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March | TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 461,65 | +0,09 % | Vertex Aktie: Strahlende Aussichten entwickeln sich! | Führende Köpfe des Biotechnologieunternehmens Vertex Pharmaceuticals Inc. haben kürzlich Aktien im erheblichen Umfang verkauft. Die Transaktion erfolgte zu einem Zeitpunkt, an dem die Vertex-Aktie eine... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 5,926 | +8,50 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 69,53 | +2,04 % | Edwards Lifesciences CFO Scott Ullem verkauft Aktien im Wert von 796.000 US-Dollar | ||
| BAUSCH HEALTH | 7,072 | -3,06 % | Bausch Health Companies Inc.: Bausch Health Announces Fourth Quarter and Full-Year 2024 Results | Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidanceFourth Quarter Consolidated Revenues... ► Artikel lesen | |
| BIONANO GENOMICS | 3,980 | -4,33 % | Bionano Genomics: Bionano Announces Effective Date of Reverse Stock Split | SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO)(the "Company") today announced that it will effect a reverse stock split of its issued and outstanding common stock... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 6,105 | -5,05 % | Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem | -- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum --
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches... ► Artikel lesen | |
| AMARIN | 0,520 | +5,26 % | Amarin Corporation plc: Amarin Marks Key Milestone for VASCEPA/VAZKEPA (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol ... | -- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with... ► Artikel lesen | |
| OPKO HEALTH | 1,677 | +0,72 % | OPKO Health, Inc.: OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results | MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the... ► Artikel lesen | |
| JAGUAR HEALTH | 0,570 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value | Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion diseaseFDA... ► Artikel lesen | |
| ENDO | - | - | Endo, Inc.: Endo Presents Healthcare Provider Survey at Joint Meeting of International Society for the Study of Women's Sexual Health (ISSWSH) and International Society for Sexual Medicine (ISSM) | MALVERN, Pa., Feb. 27, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today a presentation related to Peyronie's disease will be shared during the International Society for the Study... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OREXO AB finden Sie auf Wallstreet Online.
